Nawej Tshikung Olivier, Segeral Olivier, Cavassini Matthias, Calmy Alexandra
Unité VIH/sida, Service des maladies infectieuses, Hôpitaux universitaires de Genève, 1211 Genève 14.
Service des maladies infectieuses, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Rev Med Suisse. 2023 Feb 1;19(812):243-249. doi: 10.53738/REVMED.2023.19.812.243.
Long-acting injectable therapies have been added to the pharmacological arsenal available for the management of HIV infection, whether in the form of monotherapy (injectable cabotegravir) as part of pre-exposure prophylaxis (PrEP) or dual therapies (injectable cabotegravir/rilpivirine) for the treatment of HIV. These treatments are the subject of new international recommendations following the publication of pivotal trials, the results of which will be presented in this review. We will also discuss the practical modalities of their implementation as well as the challenges to be faced in the future.
